3SBio Inc (HKEX: 1530), a fully-integrated biotechnology company in China, has collaborated with Taiwan-based Taiwan Liposome Company Ltd (Nasdaq: TLC)( TWO: 4152).
It was reported yesterday that the collaboration is aimed at commercialising in mainland China, two liposomal products using Taiwan Liposome Company Ltd's proprietary NanoX technology platform in the therapeutic areas of oncology and severe infectious diseases.
Under this partnerships, both firms will cooperate to obtain regulatory approvals in mainland China, and TLC will use its commercial-scale manufacturing capabilities to provide the two liposomal products for 3SBio to commercialise in mainland China. Both firms also agreed to further collaboration in researching and developing other novel liposomal products in the therapeutic areas of osteoarthritis, pain management, ophthalmology, and oncology.
As per the agreement, TLC is eligible to receive up to USD25m in upfront payments for each product and subsequent regulatory and sales milestone payments. TLC is also eligible for a share of the potential profits from product sales. No other financial terms were disclosed.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial